COLUMBUS, Ohio – The Ohio State University plans to invest $16.7 million over five years in interdisciplinary projects focused on such global issues as poverty and infectious diseases, Business First of Columbus reported Wednesday.
The investment initially will support two centers for innovation and three innovation groups, according to a press release.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
OSU announced that the new centers will tackle international poverty and the global food supply. The innovation groups, which have the potential to grow into centers, will revolve around three separate tasks:
- studying complex systems and creating models to predict behavior
- addressing ethical issues in all areas of life
- investigating what causes the spread of infectious diseases and how to control them
“Without a doubt, solving our most pressing problems will require new, collaborative approaches that incorporate the full breadth and depth of faculty expertise,” OSU President E. Gordon Gee said in a statement. “Applying the university’s great range of resources to address fundamental human and community needs is at the very core of our noble public purpose.”
Proposals for centers of innovation were required to involve at least 30 faculty members from a minimum of eight colleges, while proposals for innovation groups were required to involve at least 10 faculty members from a minimum of three colleges, according to the press release.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
More stories worth a read:
- Ohio hospitals shine in annual study of patient outcomes (Cleveland Plain Dealer)
- Public option is next big hurdle in health debate (New York Times)
- New conflict rules at medical journals (Wall Street Journal)
- Neuroscience for the Twitter generation (Medicine and Technology)
- Physicians must decide whether to accept change (BNET)
- UC’s research funds up $25M (Cincinnati Enquirer)
- Gillette plans $45M expansion in St. Paul (Minneapolis/St. Paul Business Journal)
- Senate Finance bill: Drug industry likes it, unions don’t (Wall Street Journal)
- Michigan hospital to cut physician pay (American Medical News)
- FDA: Who owns health data? Durable, intractable problem (mobihealthnews)
- How far should companies go to help workers be healthy? (Wall Street Journal)
- Twin Cities health care rivals to work together (Minneapolis-St. Paul Star Tribune)
